The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:March 2015
Contact:Charles Simone, MD
Email:PennCancerTrials@emergingmed.com
Phone:855-216-0098

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The primary objective of this study is to determine whether circulating tumor cells (CTCs)
can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage
I) non-small cell lung cancer (NSCLC). Patients scheduled to undergo surgical intervention
will have blood samples obtained to test for CTCs. Presence of CTCs will be compared to
final pathologic diagnosis based on surgical specimens to assess the sensitivity of using
CTCs alone to make a definitive diagnosis.


Inclusion Criteria:

1. Clinical diagnosis of stage I NSCLC a. Only patients with a pathologically confirmed
NSCLC will be retained for data analysis b. Should pathologic diagnosis reveal a more
advanced stage, these subjects will remain in the study

2. 18 years of age

3. Ability to read and sign informed consent

4. Both men and women and members of all races and ethnic groups are eligible for this
trial.

Exclusion Criteria:

1. Prior cancer diagnosis, excluding previously treated non-melanoma skin cancer

2. Prior or ongoing treatment of the clinically diagnosed cancer
We found this trial at
1
site
Abramson Cancer Center of the University of Pennsylvania
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials